High dose therapy in localised cancer of the prostate using conformal radiotherapy techniques

Not Applicable

Completed

• Conditions: Cancer; Malignant neoplasm of the prostate

• Registration Number: ISRCTN47772397
• Lead Sponsor: Medical Research Council (MRC) (UK)

Brief Summary

2004 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/15297138 protocol 2004 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/15622611 questionnaire 2006 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/16828908 protocol 2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16949694 results on erectile dysfunction and radiotherapy 2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17155990 results on quality of life 2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17391791 results on early toxicity of escalated Vs standard dose conformal radiotherapy 2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17482880 results on escalated Vs standard dose conformal radiotherapy 2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19826203 results on correlations between spatial distribution of the dose to the rectal wall and late rectal toxicity 2010 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19540054 results on dose-volume constraints to reduce rectal side effects 2010 Results article in http://www.ncbi.nlm.nih.gov/pubmed/20443499 results 2011 Results article in http://www.ncbi.nlm.nih.gov/pubmed/21386140 modellin late rectal toxicities results 2011 Results article in http://www.ncbi.nlm.nih.gov/pubmed/21470834 results 2012 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/22169268 prospective analysis study 2012 Results article in http://www.ncbi.nlm.nih.gov/pubmed/22119373 additional rectal toxicity endpoint results 2012 Results article in http://www.ncbi.nlm.nih.gov/pubmed/22520267 results 2014 Results article in http://www.ncbi.nlm.nih.gov/pubmed/24581940 long-term results 2017 Other publications in https://www.ncbi.nlm.nih.gov/pubmed/28352980 secondary data analysis 2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29307509 two-years postradiotherapy biopsies results (added 15/03/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2000-04-06
• Study Completion: 2001-12-31
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 843

Inclusion Criteria

1. Cancer of the prostate T1b-T3a, N0, M0
2. Prostate-Specific Antigen (PSA) less than 50 ng/ml
3. World Health Organisation (WHO) 0 or 1
4. No prior radiotherapy or prostatectomy
5. No previous androgen deprivation
6. No hip prosthesis or other condition precluding radiotherapy
7. Written informed consent

Exclusion Criteria

Does not meet inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ocal tumour control, incidence of biochemical failure, metastases, survival, side effects of radiation, quality of life and health economic resources

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration